US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)

5.19

-0.2000-3.71%

Post-market: 5.190.00000.00%17:20 EDT

Volume:1.10M

Turnover:5.71M

Market Cap:502.65M

PE:-2.03

High:5.34

Open:5.30

Low:5.13

Close:5.39

52wk High:6.95

52wk Low:2.34

Shares:96.85M

Float Shares:93.76M

Volume Ratio:0.62

T/O Rate:1.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5505

EPS(LYR):-2.5505

ROE:-301.86%

ROA:-113.18%

PB:-5404.84

PE(LYR):-2.03

Loading ...

Overview Company News Filings

Statement of CDIs on issue - AVR-AVR.O

Results of Meeting-AVR.O

Anteris Technologies Global Corp-Annual Meeting CEO Presentation

THOMSON REUTERS

Notification of cessation of securities - AVR-AVR.O

Anteris Technologies Global Corp - Not Renewing Agreement With 4C Medical - SEC Filing

THOMSON REUTERS

Anteris Technologies Global Corp - No Early Termination Penalties for Non-Renewal - SEC Filing

THOMSON REUTERS

BRIEF-Anteris Technologies Global To Offer Up To 9.1 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing

Anteris Technologies Global Corp - to Offer up to 9.1 Mln Shares of Common Stock by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Anteris Technologies Global Corp Says FDA Approves Duravr THV Global Pivotal Trial

Anteris Technologies Reports Positive 30-Day Results for DurAVR THV in Severe Aortic Stenosis Trial

AVR Presents Data from 100 DurAVR THV Patients-AVR.O

Anteris Technologies Glb Q3 EPS $(0.62) Misses $(0.57) Estimate, Sales $429.000K Beat $400.000K Estimate

Anteris Technologies posts $16.8 million R&D expenses and $5.8 million SG&A expenses in Q3 2025

Press Release: Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies Global Corp-Quarterly Results Announcement and SEC Form 10-Q

THOMSON REUTERS

Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025

Notice of General Meeting/Proxy Form-AVR.O

Application for quotation of securities - AVR-AVR.O

Statement of CDIs on issue - AVR-AVR.O

FDA Approves Anteris to Begin PARADIGM Trial for DurAVR Heart Valve

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"AVR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR\",,,,,undefined,":{"symbol":"AVR","market":"US","secType":"STK","nameCN":"Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)","latestPrice":5.19,"timestamp":1774641600000,"preClose":5.39,"halted":0,"volume":1097545,"hourTrading":{"tag":"盘后","latestPrice":5.19,"preClose":5.19,"latestTime":"17:20 EDT","volume":340574,"amount":1767579.26,"timestamp":1774646413953,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03710575139146555,"floatShares":93757000,"shares":96849700,"eps":-2.550534,"marketStatus":"Market Closed","change":-0.2,"latestTime":"03-27 16:00:00 EDT","open":5.3,"high":5.34,"low":5.13,"amount":5707981.428145001,"amplitude":0.038961,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.550534,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1734066000000,"exchange":"NASDAQ","adjPreClose":5.39,"preHourTrading":{"tag":"盘前","latestPrice":5.4634,"preClose":5.39,"latestTime":"08:00 EDT","volume":2500,"amount":13694.099250000001,"timestamp":1774612804899,"change":0.0734,"changeRate":0.013618,"amplitude":0.006568},"postHourTrading":{"tag":"盘后","latestPrice":5.19,"preClose":5.19,"latestTime":"17:20 EDT","volume":340574,"amount":1767579.26,"timestamp":1774646413953,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.61732,"impliedVol":0.7347,"impliedVolPercentile":0.2609},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR\",,,,,undefined,":{"symbol":"AVR","floatShares":93757000,"roa":"-113.18%","roe":"-301.86%","lyrEps":-2.550534,"volumeRatio":0.61732,"shares":96849700,"dividePrice":0,"high":5.34,"amplitude":0.038961,"preClose":5.39,"low":5.13,"week52Low":2.34,"pbRate":"-5404.84","psRate":"262.75","week52High":6.9494,"institutionHeld":0,"latestPrice":5.19,"eps":-2.550534,"divideRate":0,"volume":1097545,"delay":0,"ttmEps":-2.550534,"open":5.3,"prevYearClose":4.99,"prevWeekClose":5.6,"prevMonthClose":6.51,"prevQuarterClose":4.99,"fiveDayClose":5.6,"twentyDayClose":6.51,"sixtyDayClose":5.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-26","symbol":"AVR","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-11-12","symbol":"AVR","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2025-08-11","symbol":"AVR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.58},{"market":"US","date":"2025-05-13","symbol":"AVR","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1773288000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVR","date":"2026-03-27","current":-2.034868,"percent":0.137072,"low":-7.464177,"twenty":-3.510904,"median":-2.24429,"eighty":-1.705773,"high":-1.284919,"avg":-2.843577,"sd":1.614173,"marketCap":530087039.27},"quantilePoints":[{"date":"2024-12-13","current":-4.309469,"twenty":-3.954542,"median":-3.42215,"eighty":-2.889759,"marketCap":241785702.43},{"date":"2024-12-20","current":-2.805718,"twenty":-4.172089,"median":-3.512177,"eighty":-2.811361,"marketCap":201352959.62},{"date":"2024-12-27","current":-2.583453,"twenty":-3.622571,"median":-2.805718,"eighty":-2.757968,"marketCap":185402037.34},{"date":"2025-01-03","current":-2.649507,"twenty":-3.534256,"median":-2.762782,"eighty":-2.579368,"marketCap":190142423.87},{"date":"2025-01-10","current":-2.852132,"twenty":-3.175408,"median":-2.762782,"eighty":-2.600721,"marketCap":204683859.73},{"date":"2025-01-17","current":-3.002665,"twenty":-2.971604,"median":-2.819825,"eighty":-2.634597,"marketCap":215486892.65},{"date":"2025-01-24","current":-2.851831,"twenty":-2.948519,"median":-2.851981,"eighty":-2.666015,"marketCap":204662263.45},{"date":"2025-01-31","current":-2.906655,"twenty":-2.944586,"median":-2.853802,"eighty":-2.693654,"marketCap":208596707.81},{"date":"2025-02-07","current":-3.031153,"twenty":-3.019758,"median":-2.892021,"eighty":-2.72197,"marketCap":217531318.5},{"date":"2025-02-14","current":-4.028787,"twenty":-3.122985,"median":-2.906655,"eighty":-2.759894,"marketCap":289126773.99},{"date":"2025-02-21","current":-4.026548,"twenty":-3.600492,"median":-2.934832,"eighty":-2.768401,"marketCap":288966072.36},{"date":"2025-02-28","current":-3.495725,"twenty":-3.645669,"median":-2.944494,"eighty":-2.793846,"marketCap":250871469.3},{"date":"2025-03-07","current":-3.832499,"twenty":-3.790793,"median":-2.978055,"eighty":-2.807758,"marketCap":275040122.18},{"date":"2025-03-14","current":-3.416065,"twenty":-3.648727,"median":-3.062965,"eighty":-2.819522,"marketCap":260615031.45},{"date":"2025-03-21","current":-2.912731,"twenty":-3.6348,"median":-3.094777,"eighty":-2.837512,"marketCap":222215144.46},{"date":"2025-03-28","current":-2.210641,"twenty":-3.611075,"median":-2.99036,"eighty":-2.768401,"marketCap":168652007.07},{"date":"2025-04-04","current":-1.681137,"twenty":-3.559327,"median":-2.950896,"eighty":-2.657761,"marketCap":128255615.11},{"date":"2025-04-11","current":-1.42483,"twenty":-3.533246,"median":-2.940881,"eighty":-2.567927,"marketCap":108701753.26},{"date":"2025-04-17","current":-1.381221,"twenty":-3.521148,"median":-2.932645,"eighty":-2.443141,"marketCap":105374733.95},{"date":"2025-04-25","current":-2.267775,"twenty":-3.514553,"median":-2.906655,"eighty":-2.267775,"marketCap":173010794.47},{"date":"2025-05-02","current":-2.264443,"twenty":-3.512177,"median":-2.892021,"eighty":-2.267775,"marketCap":172756626.85},{"date":"2025-05-09","current":-2.138136,"twenty":-3.50581,"median":-2.853802,"eighty":-2.138136,"marketCap":163120562.04},{"date":"2025-05-16","current":-1.930992,"twenty":-3.495725,"median":-2.842881,"eighty":-2.048426,"marketCap":157964762.12},{"date":"2025-05-23","current":-1.529866,"twenty":-3.47072,"median":-2.805718,"eighty":-1.914202,"marketCap":125150696.65},{"date":"2025-05-30","current":-1.846631,"twenty":-3.452168,"median":-2.762782,"eighty":-1.892505,"marketCap":151063610.88},{"date":"2025-06-06","current":-2.0132,"twenty":-3.427608,"median":-2.694374,"eighty":-1.855525,"marketCap":164689842.12},{"date":"2025-06-13","current":-2.055267,"twenty":-3.417377,"median":-2.612233,"eighty":-1.892505,"marketCap":168131158.71},{"date":"2025-06-20","current":-1.715537,"twenty":-3.345636,"median":-2.585759,"eighty":-1.853351,"marketCap":140339523.07},{"date":"2025-06-27","current":-1.809035,"twenty":-3.256784,"median":-2.563535,"eighty":-1.812529,"marketCap":147988126.84},{"date":"2025-07-03","current":-1.627995,"twenty":-3.205309,"median":-2.520408,"eighty":-1.772538,"marketCap":133178156.79},{"date":"2025-07-11","current":-1.530591,"twenty":-3.153512,"median":-2.419568,"eighty":-1.736006,"marketCap":125209987.53},{"date":"2025-07-18","current":-1.4804,"twenty":-3.126561,"median":-2.343221,"eighty":-1.703697,"marketCap":121104101.13},{"date":"2025-07-25","current":-1.412461,"twenty":-3.122985,"median":-2.267775,"eighty":-1.677031,"marketCap":115546339.43},{"date":"2025-08-01","current":-1.474074,"twenty":-3.114482,"median":-2.247212,"eighty":-1.637091,"marketCap":120586665.81},{"date":"2025-08-08","current":-1.590163,"twenty":-3.099273,"median":-2.207904,"eighty":-1.591309,"marketCap":130083291.95},{"date":"2025-08-15","current":-1.578942,"twenty":-3.069327,"median":-2.139819,"eighty":-1.587911,"marketCap":132523707.31},{"date":"2025-08-22","current":-1.545248,"twenty":-3.019758,"median":-2.094237,"eighty":-1.577141,"marketCap":129695762.64},{"date":"2025-08-29","current":-1.570053,"twenty":-2.992821,"median":-2.030879,"eighty":-1.577141,"marketCap":131777665.25},{"date":"2025-09-05","current":-1.677383,"twenty":-2.972718,"median":-1.990098,"eighty":-1.579714,"marketCap":140786140.93},{"date":"2025-09-12","current":-2.10128,"twenty":-2.951274,"median":-1.966995,"eighty":-1.583525,"marketCap":176364641.03},{"date":"2025-09-19","current":-2.245817,"twenty":-2.949708,"median":-2.013266,"eighty":-1.587161,"marketCap":188495913.06},{"date":"2025-09-26","current":-1.786155,"twenty":-2.94477,"median":-2.0132,"eighty":-1.590736,"marketCap":149915580.36},{"date":"2025-10-03","current":-1.836113,"twenty":-2.942772,"median":-1.977162,"eighty":-1.595045,"marketCap":154108633.04},{"date":"2025-10-10","current":-2.052309,"twenty":-2.93715,"median":-1.971576,"eighty":-1.604811,"marketCap":172254407.68},{"date":"2025-10-17","current":-2.083243,"twenty":-2.933957,"median":-1.976752,"eighty":-1.612531,"marketCap":174850695.44},{"date":"2025-10-24","current":-2.461764,"twenty":-2.926913,"median":-1.988526,"eighty":-1.617234,"marketCap":206620780},{"date":"2025-10-31","current":-1.990765,"twenty":-2.911516,"median":-2.002921,"eighty":-1.622674,"marketCap":167088901.63},{"date":"2025-11-07","current":-1.722091,"twenty":-2.905895,"median":-1.990765,"eighty":-1.628785,"marketCap":144538557.11},{"date":"2025-11-14","current":-1.933523,"twenty":-2.902854,"median":-1.988371,"eighty":-1.632206,"marketCap":162284456.32},{"date":"2025-11-21","current":-1.659209,"twenty":-2.898521,"median":-1.985632,"eighty":-1.636747,"marketCap":139901191.46},{"date":"2025-11-28","current":-1.921451,"twenty":-2.881188,"median":-1.981928,"eighty":-1.650736,"marketCap":162012915.47},{"date":"2025-12-05","current":-2.115337,"twenty":-2.867587,"median":-1.982339,"eighty":-1.65233,"marketCap":178360987.03},{"date":"2025-12-12","current":-2.452433,"twenty":-2.853802,"median":-1.986966,"eighty":-1.657119,"marketCap":206784230.1},{"date":"2025-12-19","current":-2.459167,"twenty":-2.852132,"median":-1.989645,"eighty":-1.659209,"marketCap":207352007.95},{"date":"2025-12-26","current":-2.520907,"twenty":-2.851891,"median":-2.002921,"eighty":-1.66186,"marketCap":212557818.95},{"date":"2026-01-02","current":-2.428806,"twenty":-2.841092,"median":-2.01799,"eighty":-1.665918,"marketCap":204792083.81},{"date":"2026-01-09","current":-2.42129,"twenty":-2.823125,"median":-2.039525,"eighty":-1.668399,"marketCap":204158355.74},{"date":"2026-01-16","current":-2.289635,"twenty":-2.809799,"median":-2.050368,"eighty":-1.672474,"marketCap":193057418.14},{"date":"2026-01-23","current":-7.272225,"twenty":-2.844671,"median":-2.069255,"eighty":-1.676009,"marketCap":613179525.66},{"date":"2026-01-30","current":-7.133108,"twenty":-2.875748,"median":-2.10128,"eighty":-1.677383,"marketCap":601449413.62},{"date":"2026-02-06","current":-5.943704,"twenty":-2.910301,"median":-2.116122,"eighty":-1.678405,"marketCap":501161244.69},{"date":"2026-02-13","current":-6.355543,"twenty":-2.941511,"median":-2.137978,"eighty":-1.680418,"marketCap":535886692.44},{"date":"2026-02-20","current":-6.52578,"twenty":-2.951274,"median":-2.141502,"eighty":-1.682984,"marketCap":550240666.81},{"date":"2026-02-27","current":-6.452717,"twenty":-3.025538,"median":-2.168616,"eighty":-1.691446,"marketCap":607484611.29},{"date":"2026-03-06","current":-6.492431,"twenty":-3.123105,"median":-2.207904,"eighty":-1.697135,"marketCap":611223361.04},{"date":"2026-03-13","current":-6.666071,"twenty":-3.230985,"median":-2.225944,"eighty":-1.702798,"marketCap":627570530.53},{"date":"2026-03-20","current":-6.114869,"twenty":-3.442549,"median":-2.238594,"eighty":-1.703533,"marketCap":575678235.22},{"date":"2026-03-27","current":-5.630598,"twenty":-3.510904,"median":-2.24429,"eighty":-1.705773,"marketCap":530087039.27}],"updateTime":1774740804222},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589851566","title":"Statement of CDIs on issue - AVR-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2589851566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589851566?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:03","pubTimestamp":1764896624,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251205:nASX9CGXdR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nASX3XGvx9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2588307447","title":"Results of Meeting-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2588307447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588307447?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:46","pubTimestamp":1764816392,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251204:nASX82mQ32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nASX1vQ9wl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2588209600","title":"Anteris Technologies Global Corp-Annual Meeting CEO Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588209600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588209600?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:16","pubTimestamp":1764803781,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUE58XQSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2588064163","title":"Notification of cessation of securities - AVR-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2588064163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588064163?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:33","pubTimestamp":1764714830,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251202:nASX7cLNbK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nASXfm4jl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2588870538","title":"Anteris Technologies Global Corp - Not Renewing Agreement With 4C Medical - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588870538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588870538?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:45","pubTimestamp":1764625516,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2588705385","title":"Anteris Technologies Global Corp - No Early Termination Penalties for Non-Renewal - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588705385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588705385?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:45","pubTimestamp":1764625516,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70YR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2586295374","title":"BRIEF-Anteris Technologies Global To Offer Up To 9.1 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586295374","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586295374?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:40","pubTimestamp":1764196838,"startTime":"0","endTime":"0","summary":"BRIEF-Anteris Technologies Global To Offer Up To 9.1 Million Shares Of Common Stock By The Selling Stockholders - SEC FilingNov 26  - Anteris Technologies Global Corp AVR.O:ANTERIS TECHNOLOGIES GLOBAL CORP - TO OFFER UP TO 9.1 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILINGSource text: [ID:n0001140361-25-043521]Further company coverage: AVR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X210X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"gpt_icon":1},{"id":"2586298669","title":"Anteris Technologies Global Corp - to Offer up to 9.1 Mln Shares of Common Stock by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298669","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586298669?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:37","pubTimestamp":1764193021,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X210X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2584781923","title":"Anteris Technologies Global Corp Says FDA Approves Duravr THV Global Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584781923","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584781923?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:20","pubTimestamp":1763569256,"startTime":"0","endTime":"0","summary":"Nov 3 (Reuters) - Anteris Technologies Global Corp ::*FDA APPROVES DURAVR THV GLOBAL PIVOTAL TRIAL*Further company coverage: AVR.O* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 02-NOV-202518:37:24.187 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1h9KQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2584423216","title":"Anteris Technologies Reports Positive 30-Day Results for DurAVR THV in Severe Aortic Stenosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584423216","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584423216?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377227,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp. has announced the 30-day clinical outcomes for its DurAVR transcatheter heart valve  in 100 patients with severe aortic stenosis and small aortic annuli. The results, presented at the PCR London Valves conference and published in EuroIntervention, showed a favorable hemodynamic profile, with a mean effective orifice area of 2.2 ± 0.3 cm and a mean pressure gradient of 8.2 ± 3.1 mmHg. No valve-related mortality or moderate to severe paravalvular leak was observed at 30 days, and prosthesis-patient mismatch was reported at 3.0%. The study achieved a technical success rate of 100% in the last 50 consecutive cases. These findings are part of ongoing research ahead of the larger PARADIGM Trial, which will compare DurAVR THV with commercially available transcatheter aortic valve replacements in a randomized controlled setting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL5jLy3r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","BK4585","LU0314104364.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","BK4082","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","AVR","BK4112"],"gpt_icon":0},{"id":"2584699470","title":"AVR Presents Data from 100 DurAVR THV Patients-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2584699470","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584699470?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:48","pubTimestamp":1763333306,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251116:nASXbx257L","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nASX6CKcyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2583258144","title":"Anteris Technologies Glb Q3 EPS $(0.62) Misses $(0.57) Estimate, Sales $429.000K Beat $400.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258144","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258144?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:02","pubTimestamp":1762988536,"startTime":"0","endTime":"0","summary":"Anteris Technologies Glb Q3 EPS $(0.62) Misses $(0.57) Estimate, Sales $429.000K Beat $400.000K Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48822326/anteris-technologies-glb-q3-eps-0-62-misses-0-57-estimate-sales-429-000k-beat-400-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Anteris Technologies Glb Q3 EPS $(0.62) Misses $(0.57) Estimate, Sales $429.000K Beat $400.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2583581693","title":"Anteris Technologies posts $16.8 million R&D expenses and $5.8 million SG&A expenses in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581693","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581693?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:53","pubTimestamp":1762987981,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp. reported net operating cash outflows of $59.3 million for the nine months ended September 30, 2025, reflecting increased clinical, regulatory, and manufacturing activities related to the PARADIGM Trial. For the three months ended September 30, 2025, research and development expenses were $16.8 million, and selling, general and administrative expenses were $5.8 million. The company held $9.1 million in cash and cash equivalents as of September 30, 2025. During the quarter, Anteris advanced its quality management system, expanded manufacturing capacity, and received regulatory approvals to commence the PARADIGM Trial in the U.S. and Denmark.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technolo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7vwwSt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","AVR","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK7126","NDAQ","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4082","AVR.AU","BK7007","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD"],"gpt_icon":0},{"id":"2583619581","title":"Press Release: Anteris Announces Results for the Third Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583619581","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583619581?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:52","pubTimestamp":1762987920,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025  -- Anteris Technologies Global Corp.   a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update.-- Continued FDA engagement during the Quarter to advance the IDE for the. PARADIGM Trial, with FDA approval to commence U.S. recruitment* announced. across multiple countries, with the first PARADIGM patients treated in. Anteris also advanced European regulatory activities aimed at securing approval to commence the PARADIGM Trial in countries including Germany, France and the Netherlands, with the first European approval secured in Denmark in October 2025. In parallel, cross-functional teams completed site and operational readiness activities, namely investigator training, study material preparation, and logistical set up, ahead of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082","BK4159","BK4022","IDE","RCT","BK4232","R"],"gpt_icon":0},{"id":"2583991589","title":"Anteris Technologies Global Corp-Quarterly Results Announcement and SEC Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2583991589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583991589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:24","pubTimestamp":1762986262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE6FRF6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2583586898","title":"Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583586898","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583586898?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in womenNEDA study of 1.2M patie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186797/0/en/Echo-IQ-Highlights-Market-Potential-for-EchoSolv-AS-Following-Presentation-of-New-Data-for-Severe-Aortic-Stenosis-AS-Presented-at-AHA-Scientific-Sessions-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","AS","BK4202","BK4108","BK4531","IQ","BK4505","BK4082","AVR","BK4552"],"gpt_icon":0},{"id":"2582079386","title":"Notice of General Meeting/Proxy Form-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2582079386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582079386?lang=en_us&edition=fundamental","pubTime":"2025-11-11 06:36","pubTimestamp":1762814180,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nASXGjg5Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nASX1v1DxW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2581058133","title":"Application for quotation of securities - AVR-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2581058133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581058133?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:34","pubTimestamp":1762410859,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251106:nASX1FyF35","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nASXbDkC4q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AVR"],"gpt_icon":0},{"id":"2581808456","title":"Statement of CDIs on issue - AVR-AVR.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2581808456","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581808456?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:11","pubTimestamp":1762387917,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251106:nASXb62pf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nASXszhSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082"],"gpt_icon":0},{"id":"2580629757","title":"FDA Approves Anteris to Begin PARADIGM Trial for DurAVR Heart Valve","url":"https://stock-news.laohu8.com/highlight/detail?id=2580629757","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580629757?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:01","pubTimestamp":1762171278,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp. has received approval from the U.S. Food and Drug Administration  to initiate the PARADIGM global Investigational Device Exemption  clinical trial. The trial will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve  in patients with severe calcific aortic stenosis and is intended to support a future premarket approval  submission. This regulatory milestone also allows Anteris to begin patient recruitment in the United States, following the successful launch and treatment of initial patients in Denmark. The PARADIGM Trial is co-chaired by leading cardiovascular experts from Houston Methodist Hospital, Texas, and Bern University Hospital, Switzerland. No grant or funding was announced for multiple organizations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL8cWvSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4082","BK4588","BK4112","IE00BKPKM429.USD","NDAQ","AVR","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":114,"code":"91000000","status":"200"}]}}